Medical Equipment

Breast Cancer Liquid Biopsy Market Analysis Highlighting Growth Potential And Outlook

April 10, 2026April 10, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Breast Cancer Liquid Biopsy Market Compare Between 2026 And 2030?

The breast cancer liquid biopsy market size has seen rapid expansion in recent years. It is anticipated to grow from $0.89 billion in 2025 to $1.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. The historical increase in this market can be attributed to several factors such as rising breast cancer prevalence, limitations of tissue biopsy, oncology diagnostic advancements, increased screening awareness, and laboratory testing expansion.

The breast cancer liquid biopsy market is anticipated to undergo significant expansion in the coming years, with its size projected to reach $1.75 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.3%. This expansion during the forecast period is primarily due to factors like precision oncology adoption, AI-based mutation analysis, personalized treatment planning, growth in cfDNA testing, and decentralized cancer diagnostics. Prominent trends for this period include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment response tracking, early recurrence detection, and personalized oncology diagnostics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Which Primary Drivers Are Impacting The Breast Cancer Liquid Biopsy Market Growth?

The increasing number of breast cancer cases is projected to drive the expansion of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that forms in the breast’s cells, typically within the lobules (milk-producing glands) or ducts (pathways that transport milk to the nipple). The growing occurrence of breast cancer is influenced by factors including genetic predisposition, hormonal imbalances, an aging demographic, changes in lifestyle, obesity, alcohol consumption, insufficient physical activity, exposure to radiation, and environmental pollutants. A breast cancer liquid biopsy is employed in treatment to identify circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, facilitating real-time disease monitoring. It plays a role in evaluating treatment effectiveness, detecting resistance to therapy, and pinpointing genetic mutations for targeted interventions. For instance, in 2025, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, the count of new breast cancer cases is anticipated to climb to 319,750 in 2025, an increase from 313,510 cases in 2024. Consequently, the rise in breast cancer cases is propelling the growth of the breast cancer liquid biopsy market.

Which Segment Types Are Examined In The Breast Cancer Liquid Biopsy Market Segment Study?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Which Trends Are Shaping Growth In The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are primarily focusing on the development of innovative products, such as companion diagnostics, to enable personalized treatment approaches by pinpointing patients who are likely to benefit from specific therapies. Companion diagnostics utilize liquid biopsy technologies to detect crucial biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test. This test functions as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a treatment intended for advanced or metastatic breast cancer patients with ESR1 mutations. This approval empowers oncologists to use the test for comprehensive genomic profiling, thereby identifying patients who may be suitable candidates for the targeted therapy. It represents Guardant Health’s inaugural U.S. Food and Drug Administration (FDA) approval in the breast cancer field and enhances its contribution to precision oncology.

Which Players Are Part Of The Competitive Landscape Of The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Get The Full Breast Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Where Is The Breast Cancer Liquid Biopsy Market Most Concentrated Geographically?

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Breast Cancer Liquid Biopsy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795